Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954

Patel, P., Young, J. G., Mautner, V., Ashdown, D., Bonney, S., Pineda, R. G., Collins, S. I., Searle, P. F., Hull, D., Peers, E., Chester, John D. ORCID:, Wallace, D. M., Doherty, A., Leung, H., Young, L. S. and James, N. D. 2009. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954. Molecular Therapy 17 (7) , pp. 1292-1299. 10.1038/mt.2009.80

Full text not available from this repository.


We report a phase I/II clinical trial in prostate cancer (PCa) using direct intraprostatic injection of a replication defective adenovirus vector (CTL102) encoding bacterial nitroreductase (NTR) in conjunction with systemic prodrug CB1954. One group of patients with localized PCa scheduled for radical prostatectomy received virus alone, prior to surgery, in a dose escalation to establish safety, tolerability, and NTR expression. A second group with local failure following primary treatment received virus plus prodrug to establish safety and tolerability. Based on acceptable safety data and indications of prostate-specific antigen (PSA) responses, an extended cohort received virus at a single dose level plus prodrug. The vector was well tolerated with minimal side effects, had a short half-life in the circulation, and stimulated a robust antibody response. Immunohistochemistry of resected prostate demonstrated NTR staining in tumor and glandular epithelium at all dose levels [5 × 1010–1 × 1012 virus particles (vp)]. A total of 19 patients received virus plus prodrug and 14 of these had a repeat treatment; minimal toxicity was observed and there was preliminary evidence of change in PSA kinetics, with an increase in the time to 10% PSA progression in 6 out of 18 patients at 6 months.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
Additional Information: This article has a correction: Molecular Therapy 17 (7) 1302, July 2009. Following the online publication of this article, the authors noted an error in the article title. The correct title is “A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase With CB1954.”
Publisher: Nature Publishing Group
ISSN: 1525-0016
Related URLs:
Last Modified: 13 May 2024 12:38

Citation Data

Cited 73 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item